IVC THROMBECTOMY: OPEN Gennady Bratslavsky, M.D. Professor and - - PowerPoint PPT Presentation
IVC THROMBECTOMY: OPEN Gennady Bratslavsky, M.D. Professor and - - PowerPoint PPT Presentation
IVC THROMBECTOMY: OPEN Gennady Bratslavsky, M.D. Professor and Chairman Department of Urology SUNY Upstate Medical University Syracuse, NY Disclosures None I am not an ideal candidate to argue for open IVC thrombectomy I have
Disclosures
None I am not an ideal candidate to argue for open IVC
thrombectomy
I have performed minimally-invasive IVC thrombectomies since 2011
First level 3 IVC thrombectomy with robot (still the
largest one in the literature) with RPLND
Last month I have done 2 IVC cases with a robot
Direct invasion of the IVC wall in several places requiring
complete replacement with Gor-Tex graft
T4 with liver invasion and IVC thrombus
49 year old women (350 lbs, ECOG 1)
- Patient discharged 36 hours post op
- Path: pT3b, N0, clear cell carcinoma, Grade 3
- 44 lymph nodes negative
Definitions
Suprahepatic Suprarenal Infrarenal
Levels of Tumor Thrombus
I 42% III 12% IV 5% <2 cm into IVC Suprarenal Intracardiac II 22%
Yet, I will argue for OPEN technique today
For majority, the robotic IVC is still a VERY
selected group
Level 1 does not count True level 3 with Pringle and suprahepatic control is
too long and dangerous
Level 4 is not there yet
Video at the AUA “controlled piece meal removal”
Venous involvement in RCC Patients
Incidence % Authors
Venous invasion
4-36
Skinner, 1972 Novick, 1980 Marshall, 1988 Hatcher, 1991 Pouliot, 2010
IVC extension
3-5
Kearney, 1981 Libertino, 1987
Atrial extension
0.5-1.0
Neves/ Zincke, 1987
Surgical Principles for Tumor Thrombectomy
1. Assemble experienced team
Anesthesia +/- Hepatobiliary, vascular, cardiac surgery
2. Operate on vessels first (preserve collateralized veins if IVC occluded) 3. Ligate renal artery, no need to embolize 4. Isolate venous structures 5. Completely remove thrombus 6. Manage any distal bland thrombus 7. Repair/patch/replace IVC as needed 8. Complete nephrectomy and LND
Exposure is Everything
Location of tumor Body habitus Veins to be isolated Costal flare
Choice of incision
Avoid Preoperative Embolization
IVC VTT cases 135 with, 90 without embolization Embolization: blood loss, complications, mortality
MVA revealed 5 fold increased risk of per operative death in patients with embolization
Several large series against embilozation
Subramanian, Urology 2009
Right Medial Visceral Rotation to Expose Suprarenal IVC
Divide ligaments to fully mobilize liver
Retrohepatic
Tumor Thrombus: Level III Technique
Renal artery ligation Mobilize liver for suprahepatic IVC access Sequence for venous control: 1. Contralateral renal vein 2. Distal IVC, incl. 2nd lumbar vein 3. Hepatic inflow (Pringle maneuver) 4. Suprahepatic IVC (above thrombus) Remove thrombus or get it below the hepatic
veins
Occlude IVC below hepatic inflow Release suprahepatic IVC & Pringle Repair vena cava leisurely Complete nephrectomy
1 2 3 4
Veno-veno bypass Cardiopulmonary bypass Cardiopulmonary bypass with hypothermic (16ºC) circulatory
arrest
Advantages: bloodless field, ~60 minutes of ischemia time
Hypothermic arrest is associated with longer OS and
significant reduction in perioperative mortality
Disadvantages: need for anticoagulation and reversal
Tumor Thrombus: Level IV Technique
Inferior Vena Cava Reconstruction
Critical to achieve complete removal of intraluminal
thrombus as well as tumor infiltrating into vein wall
Vein wall invasion may be difficult to recognize grossly –
frozen section margins useful
Patch preferred over graft, if possible Infrarenal IVC resection without replacement if vein
chronically occluded
Replacement of para- and supra-renal IVC with low
threshold to re-implant renal veins
55 y/o man with renal cell carcinoma and level IV tumor thrombus: Avoided sternotomy: Foley (level IV to level III)
Outcomes of Nephrectomy and IVC Tumor Thrombectomy (pre targeted therapy) ALL levels
Median Survival (mos.) 5-yr. DSS(%) Follow- up Author Yr n No mets Mets No mets Mets
Haferkamp
2007 111* 52 11 46 6.5 16
Karnes/Blute
2008 614**
- 55
13
- Klatte
2007 321 116 16 65 19 25
Lambert
2007 118
- 61
- 18
Sweeney
2003 96 38 20 40 28 25
Modified from Pouliot, et al. J Urol. 2010
- 162 patients
- Level 3: 69
- Level 4: 93
- Major complications: 34%
- 90 day mortality: 10.4%
- ECOG>1 and low albumin
predicted mortality
Eur Urol, 2013
Changing the paradigm:
- Prof. Vsevolod Matveev